AGN
Pharmaceuticals, Biotechnology & Life Sciences
Argenica Therapeutics
- Short interest
- 0.01%
- +0.01 pp 30d
- as of 3 July 2026
- Reported shorts
- 15.2K
- Shares on issue
- 128.457M
Argenica Therapeutics (AGN) company profile
Profile, insiders and operations
Company
AI-generated research profile of Argenica Therapeutics
neuroprotective therapeutics
stroke treatment
brain injury
biotech innovation
clinical trials
Argenica Therapeutics Limited is a biotechnology company focused on developing novel neuroprotective treatments aimed at reducing brain damage following strokes and other severe brain injuries. Positioned as an innovator in the neuroprotection field, the company leverages cutting-edge research to create therapies that can potentially transform patient outcomes.
Director trades
10 trades recorded
AGN intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Sign in to unlock the dossierFree account · no card required